Oncobiologics, Inc. (NASDAQ:OTLK) Receives $5.33 Average PT from Analysts

Shares of Oncobiologics, Inc. (NASDAQ:OTLK) have received an average rating of “Hold” from the six ratings firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $5.3333.

Several equities analysts have commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Oncobiologics in a research note on Monday, December 29th. Ascendiant Capital Markets upped their target price on shares of Oncobiologics from $8.00 to $10.00 and gave the company a “buy” rating in a report on Monday, December 22nd. Finally, Wall Street Zen lowered shares of Oncobiologics from a “hold” rating to a “sell” rating in a research note on Saturday, January 3rd.

Oncobiologics Price Performance

Oncobiologics stock opened at $0.44 on Tuesday. The stock has a market cap of $32.32 million, a PE ratio of -0.29 and a beta of 0.17. The stock’s fifty day moving average is $1.34 and its two-hundred day moving average is $1.47. Oncobiologics has a 1-year low of $0.42 and a 1-year high of $3.39.

Oncobiologics (NASDAQ:OTLK) last released its quarterly earnings data on Friday, December 19th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. The business had revenue of $4.65 million during the quarter, compared to analysts’ expectations of $5.85 million. On average, research analysts expect that Oncobiologics will post -2.27 earnings per share for the current fiscal year.

Institutional Trading of Oncobiologics

Several institutional investors and hedge funds have recently made changes to their positions in OTLK. Russell Investments Group Ltd. grew its stake in Oncobiologics by 865.2% during the 2nd quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock worth $39,000 after buying an additional 21,941 shares during the last quarter. AQR Capital Management LLC lifted its stake in Oncobiologics by 42.7% in the first quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock valued at $103,000 after buying an additional 25,351 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of Oncobiologics by 74.1% in the first quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock valued at $126,000 after acquiring an additional 44,063 shares during the period. 11.20% of the stock is owned by hedge funds and other institutional investors.

About Oncobiologics

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.